Is tigecycline dosed differently in people with liver problems?
Tigecycline labeling includes guidance for liver impairment, with dosing reduced in patients who have moderate to severe hepatic dysfunction. The adjustment is based on the patient’s Child-Pugh category rather than on liver enzyme levels alone. [1]
What happens to the tigecycline dose in Child-Pugh B vs Child-Pugh C?
For hepatic impairment:
- Child-Pugh Class B (moderate impairment): the recommended dose is reduced to 100 mg initially, then 50 mg every 12 hours. [1]
- Child-Pugh Class C (severe impairment): the recommended dose is reduced to 100 mg initially, then 25 mg every 12 hours. [1]
Do patients with mild liver impairment (Child-Pugh A) need a dose change?
Dose reduction is specifically described for moderate and severe hepatic impairment (Child-Pugh B and C). The provided dosing adjustment guidance indicates no equivalent reduction is recommended for Child-Pugh Class A. [1]
How do clinicians decide whether to adjust dosing?
Clinicians typically determine the Child-Pugh class from clinical and lab features (such as bilirubin, albumin, INR/prothrombin time, ascites, and hepatic encephalopathy) to decide whether the patient needs the reduced dosing schedule for tigecycline. [1]
Practical implications: what to watch for if liver impairment is present
Because tigecycline exposure increases in hepatic impairment, the label’s reduced maintenance dosing aims to lower drug accumulation risk in patients with moderate to severe liver dysfunction. [1]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/